Listed by the USPTO as BATES, KEENAN ALEXANDER
Tech Center 1600 • Art Units: 1631 1632
This examiner grants 45% of resolved cases
Keenan Alexander Bates serves in Tech Center 1600 and Art Unit 1631, focusing on a caseload that includes 78 resolved cases. The examiner maintains an allowance rate of 44.9 percent. The data reveals an interview lift of 79.8 percent, which suggests that interviews are a factor in moving applications toward allowance. This lift indicates a significant change in outcomes when oral communication is utilized.
The prosecution timeline shows a median of 1306 days to allowance. This duration suggests a long-term commitment for applicants seeking patent protection. The top companies appearing before this examiner include The Trustees of the University of Pennsylvania, Oxford University Innovation Limited, and University of Florida Research Foundation Inc. These institutional applicants, supported by firms such as BIRCH STEWART KOLASCH & BIRCH, LLP, FOLEY & LARDNER LLP, and GOODWIN PROCTER LLP, face the 44.9 percent allowance rate.
Given the 79.8 percent interview lift, practitioners should evaluate the role of direct communication. While the 78 resolved cases represent the current dataset, the impact of interviews is a prominent feature. The 1306-day median pendency underscores the time involved in navigating the 1600 tech center environment effectively with this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17272203 | ADENO-ASSOCIATED VIRAL VECTORS FOR THE TREATMENT OF BEST DISEASE | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17280392 | IN VITRO GROWTH METHOD FOR HAIR FOLLICULAR EPITHELIAL STEM CELLS | Non-Final OA | RIKEN |
| 18406302 | IMMUNOSELECTED UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (UC-MSCs) AND DOWNSTREAM BIOLOGICS | Non-Final OA | GLOBUS MEDICAL, INC. |
| 17600820 | Compositions and Methods for Allelic Gene Drive Systems and Lethal Mosaicism | Final Rejection | The Regents of the University of California |
| 18721402 | COMPOSITIONS AND METHODS FOR ESTABLISHMENT OF BOVINE-INDUCED PLURIPOTENT STEM CELLS | Non-Final OA | University of Connecticut |
| 18041447 | Methods of Protecting RNA | Final Rejection | Pfizer Inc. |
| 17602730 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17601581 | COMPOSITIONS AND METHODS FOR IN UTERO GENE EDITING FOR MONOGENIC LUNG DISEASE | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17669874 | PANCREATIC DIFFERENTIATION | Non-Final OA | Vertex Pharmaceuticals Incorporated |
| 18648087 | PRODUCTION METHOD OF MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF | Non-Final OA | OSAKA UNIVERSITY |
| 18021675 | METHOD OF MAKING RECOMBINANT AAVS | Final Rejection | Oxford University Innovation Limited |
| 18021691 | PROCESS FOR MAKING A RECOMBINANT AAV LIBRARY | Final Rejection | Oxford University Innovation Limited |
| 17287972 | ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY | Non-Final OA | Baylor College of Medicine |
| 18020734 | METHOD FOR THE TREATMENT OF WWOX ASSOCIATED DISEASES | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy44.9% of resolved applications examined by Keenan Alexander Bates were allowed (78 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +79.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Keenan Alexander Bates took 1,306 days on average from filing to allowance.
Keenan Alexander Bates examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
